SEC Tracker
Get the app

Halozyme Therapeutics HALO

Matthew L. Posard (affiliate) plans to sell 30,000 HALO shares, about $1.6M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Aug 13, 2024
  2. Broker: Ameriprise Financial
  3. Shares acquired by: restricted stock

All of Matthew L. Posard's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Halozyme Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  2. Alkermes ALKS public float $4.7B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.